TY - JOUR
T1 - Cell volume-activated and volume-correlated anion channels in mammalian cells
T2 - Their biophysical, molecular, and pharmacological properties
AU - Okada, Yasunobu
AU - Okada, Toshiaki
AU - Sato-Numata, Kaori
AU - Islam, Md Rafiqul
AU - Ando-Akatsuka, Yuhko
AU - Numata, Tomohiro
AU - Kubo, Machiko
AU - Shimizu, Takahiro
AU - Kurbannazarova, Ranohon S.
AU - Marunaka, Yoshinori
AU - Sabirov, Ravshan Z.
N1 - Publisher Copyright:
© 2018 by The American Society for Pharmacology and Experimental Therapeutics.
PY - 2019/1
Y1 - 2019/1
N2 - There are a number of mammalian anion channel types associated with cell volume changes. These channel types are classified into two groups: volume-activated anion channels (VAACs) and volume-correlated anion channels (VCACs). VAACs can be directly activated by cell swelling and include the volume-sensitive outwardly rectifying anion channel (VSOR), which is also called the volume-regulated anion channel; the maxi-anion channel (MAC or Maxi-Cl); and the voltage-gated anion channel, chloride channel (ClC)-2. VCACs can be facultatively implicated in, although not directly activated by, cell volume changes and include the cAMP-activated cystic fibrosis transmembrane conductance regulator (CFTR) anion channel, the Ca 2+ -activated Cl - channel (CaCC), and the acid-sensitive (or acid-stimulated) outwardly rectifying anion channel. This article describes the phenotypical properties and activation mechanisms of both groups of anion channels, including accumulating pieces of information on the basis of recent molecular understanding. To that end, this review also highlights the molecular identities of both anion channel groups; in addition to the molecular identities of ClC-2 and CFTR, those of CaCC, VSOR, and Maxi-Cl were recently identified by applying genome-wide approaches. In the last section of this review, the most up-to-date information on the pharmacological properties of both anion channel groups, especially their half-maximal inhibitory concentrations (IC 50 values) and voltage-dependent blocking, is summarized particularly from the standpoint of pharmacological distinctions among them. Future physiologic and pharmacological studies are definitely warranted for therapeutic targeting of dysfunction of VAACs and VCACs.
AB - There are a number of mammalian anion channel types associated with cell volume changes. These channel types are classified into two groups: volume-activated anion channels (VAACs) and volume-correlated anion channels (VCACs). VAACs can be directly activated by cell swelling and include the volume-sensitive outwardly rectifying anion channel (VSOR), which is also called the volume-regulated anion channel; the maxi-anion channel (MAC or Maxi-Cl); and the voltage-gated anion channel, chloride channel (ClC)-2. VCACs can be facultatively implicated in, although not directly activated by, cell volume changes and include the cAMP-activated cystic fibrosis transmembrane conductance regulator (CFTR) anion channel, the Ca 2+ -activated Cl - channel (CaCC), and the acid-sensitive (or acid-stimulated) outwardly rectifying anion channel. This article describes the phenotypical properties and activation mechanisms of both groups of anion channels, including accumulating pieces of information on the basis of recent molecular understanding. To that end, this review also highlights the molecular identities of both anion channel groups; in addition to the molecular identities of ClC-2 and CFTR, those of CaCC, VSOR, and Maxi-Cl were recently identified by applying genome-wide approaches. In the last section of this review, the most up-to-date information on the pharmacological properties of both anion channel groups, especially their half-maximal inhibitory concentrations (IC 50 values) and voltage-dependent blocking, is summarized particularly from the standpoint of pharmacological distinctions among them. Future physiologic and pharmacological studies are definitely warranted for therapeutic targeting of dysfunction of VAACs and VCACs.
UR - http://www.scopus.com/inward/record.url?scp=85058877191&partnerID=8YFLogxK
U2 - 10.1124/pr.118.015917
DO - 10.1124/pr.118.015917
M3 - 総説
C2 - 30573636
AN - SCOPUS:85058877191
SN - 0031-6997
VL - 71
SP - 49
EP - 88
JO - Pharmacological Reviews
JF - Pharmacological Reviews
IS - 1
ER -